Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.

Haikun Song, H Li, Shimeng Guo, Yuyin Pan, Yuhua Fu, Zijian Zhou, Z Li, Xue Wen, Xiaoli Sun, Bingqing He, Haifeng Gu, Quan Zhao, Cen Wang, Ping An, Shouqing Luo, Youhong Hu, Xin Xie, Boxun Lu*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Downloads (Pure)

Abstract

See Huang and Gitler (doi:10.1093/brain/awy112) for a scientific commentary on this article.Lowering the levels of disease-causing proteins is an attractive treatment strategy for neurodegenerative disorders, among which Huntington's disease is an appealing disease for testing this strategy because of its monogenetic nature. Huntington's disease is mainly caused by cytotoxicity of the mutant HTT protein with an expanded polyglutamine repeat tract. Lowering the soluble mutant HTT may reduce its downstream toxicity and provide potential treatment for Huntington's disease. This is hard to achieve by small-molecule compound drugs because of a lack of effective targets. Here we demonstrate Gpr52, an orphan G protein-coupled receptor, as a potential Huntington's disease drug target. Knocking-out Gpr52 significantly reduces mutant HTT levels in the striatum and rescues Huntington's disease-associated behavioural phenotypes in a knock-in Huntington's disease mouse model expressing endogenous mutant Htt. Importantly, a novel Gpr52 antagonist E7 reduces mutant HTT levels and rescues Huntington's disease-associated phenotypes in cellular and mouse models. Our study provides an entry point for Huntington's disease drug discovery by targeting Gpr52.
Original languageEnglish
Pages (from-to)1782-1798
Number of pages0
JournalBrain
Volume141
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Dive into the research topics of 'Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.'. Together they form a unique fingerprint.

Cite this